Prostate-specific Antigen (PSA), Ultrasensitive

The ultrasensitive PSA test measures extremely small amounts of a protein called PSA in your blood—amounts too small for regular PSA tests to detect. It is mainly used after prostate cancer treatment, such as surgery to remove the prostate, to check whether the cancer has come back. After surgery, PSA levels should be nearly zero, so even a tiny rise can be an early warning sign that needs follow-up. Your doctor will look at trends over time—not just a single result—to decide if any action is needed. This test is a monitoring tool and should always be interpreted alongside your full medical history and your doctor's clinical judgment.

When elevated: A detectable or rising ultrasensitive PSA after radical prostatectomy may indicate biochemical recurrence, residual prostatic tissue, or metastatic disease and warrants clinical evaluation. Rapidly rising values with a short PSA doubling time are associated with more aggressive disease behavior and may prompt imaging or salvage therapy discussions. When low: An undetectable or persistently very low ultrasensitive PSA after definitive therapy is associated with favorable oncologic outcomes and suggests effective disease control. However, a low value does not entirely exclude microscopic residual disease, and continued surveillance per established guidelines remains essential.

Ultrasensitive PSA is not routinely relevant to athletes or general health-conscious populations. This test is specialized for men with a history of prostate cancer treatment who need sensitive monitoring for recurrence—not for performance, recovery, or preventive health screening in athletic populations.